Results 11 to 20 of about 2,196 (157)

HDL-mimetic peptide treatment reverses APOE4-induced transcriptomic and lipidomic alterations in the brain of humanized APOE mice. [PDF]

Alzheimers Dement
Abstract INTRODUCTION The apolipoprotein E4 (APOE4) allele is the strongest genetic risk factor for late‐onset Alzheimer's disease (AD). ApoE4 has reduced lipidation capacity and impaired lipid transport, disrupting neuronal maintenance. The high‐density lipoprotein (HDL)‐mimetic peptide 4F offers a potential therapeutic strategy.
Chang A, Kim M, Glittenberg M, Qu W, Li D, Li L.   +5 more
europepmc   +2 more sources

A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids

Journal of Lipid Research, 2009
Administered subcutaneously, D-4F or L-4F are equally efficacious, but only D-4F is orally efficacious because of digestion of L-4F by gut proteases. Orally administering niclosamide (a chlorinated salicylanilide used as a molluscicide, antihelminthic ...
Alan J Waring, Mohamad Navab, Piotr Ruchala   +2 more
exaly   +3 more sources

Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. [PDF]

Circ Res, 2010
Rationale : Apolipoprotein (apoA)-I mimetic peptides are a promising type of antiatherosclerosis therapy, but how the structural features of these peptides relate to the multiple antiatherogenic functions of HDL is poorly understood.
D'Souza W, Stonik JA, Murphy A, Demosky SJ, Sethi AA, Moore XL, Chin-Dusting J, Remaley AT, Sviridov D.   +8 more
europepmc   +4 more sources

Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides [PDF]

Journal of Lipid Research, 2007
Recently, attention has been focused on pharmacological treatments that increase HDL cholesterol to prevent coronary artery disease. Despite three decades of extensive research of human apolipoprotein A-I (apoA-I), the major protein component of HDL, the
G.M. Anantharamaiah, Vinod K. Mishra, David W. Garber, Geeta Datta, Shaila P. Handattu, Mayakonda N. Palgunachari, Manjula Chaddha, Mohamad Navab, Srinivasa T. Reddy, Jere P. Segrest, Alan M. Fogelman   +10 more
doaj   +3 more sources

Tumor microenvironment-responsive conformational activation of apoA-I mimetic peptides for targeted cancer therapy [PDF]

Drug Delivery
Apolipoprotein A-I (ApoA-I) mimetic peptides have garnered attention as potential anticancer agents owing to their role in cholesterol metabolism and ability to interact with the SR-BI receptor.
Mengjie Rui, Lei Fang, Mengfei Jia, Wenyan Liang, Yinfeng Li, Yaoshun Ruan, Chunlai Feng   +6 more
doaj   +2 more sources

Differential Effects of Apolipoprotein A-I–Mimetic Peptide on Evolving and Established Atherosclerosis in Apolipoprotein E-Null Mice [PDF]

Circulation, 2004
Background— Apolipoprotein (apo) A-I and apoA-I–mimetic peptides showed promise to prevent atherosclerosis development. Using a bypassed vein graft model in apoE-null mice, we evaluated the effects of oral or intraperitoneal administration of an apoA-I–mimetic peptide on evolving atherosclerotic ...
Xiaojun Li, Sanjay Kaul, JOSÉ Faria Neto   +2 more
exaly   +3 more sources

Exploring the structure and dynamics of peptide nanodiscs through a synergistic approach with NMR spectroscopy, SAS and MD simulations [PDF]

Communications Chemistry
Peptide nanodiscs are promising anti-atherosclerosis therapeutics, drug delivery particles and structural biology tools. However, the lack of experimental methods for structural and dynamical characterization of these particles hinders their further ...
Sirine Nouri, Akseli Niemelä, Ricky Nencini, Georgios Kolypetris, Tuomas Niemi-Aro, Salla I. Virtanen, O. H. Samuli Ollila, Artturi Koivuniemi   +7 more
doaj   +2 more sources

The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit [PDF]

Lipids in Health and Disease, 2011
Background High-density lipoproteins (HDL) and their main apolipoprotein, apoA-I, exhibit anti-inflammatory properties. The development of peptides that mimic HDL apolipoproteins offers a promising strategy to reduce inflammatory disease.
Di Bartolo Belinda A, Vanags Laura Z, Tan Joanne TM, Bao Shisan, Rye Kerry-Anne, Barter Philip J, Bursill Christina A   +6 more
doaj   +3 more sources

Apolipoprotein A-I Mimetic Peptides Prevent Atherosclerosis Development and Reduce Plaque Inflammation in a Murine Model of Diabetes [PDF]

Diabetes, 2010
Mohamad Navab, Cecilia Morgantini, Grijalva VÍCTOR   +2 more
exaly   +2 more sources

Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity

Frontiers in Immunology, 2021
Apolipoprotein A-I mimetic peptides are amphipathic alpha-helix peptides that display similar functions to apolipoprotein A-I. Preclinical and clinical studies have demonstrated the safety and efficacy of apolipoprotein A-I mimetic peptides in multiple ...
Myriam Fernandez-Sendin, Myriam Fernandez-Sendin, Claudia Augusta Di Trani, Claudia Augusta Di Trani, Angela Bella, Angela Bella, Marcos Vasquez, Marcos Vasquez, Nuria Ardaiz, Nuria Ardaiz, Celia Gomar, Celia Gomar, Leire Arrizabalaga, Leire Arrizabalaga, Sergio Ciordia, Sergio Ciordia, Fernando J. Corrales, Fernando J. Corrales, Fernando Aranda, Fernando Aranda, Pedro Berraondo, Pedro Berraondo, Pedro Berraondo   +22 more
doaj   +1 more source